Cervical cancer remains one of the most common cancers among Malaysian women, with the majority of cases linked to human papillomavirus (HPV). Since Malaysia introduced school-based immunization in 2010, vaccination coverage among adolescents has been modest, while intent and uptake among adults remains low. To bridge this gap, a public awareness campaign held on September 26, 2025 at Hospital Canselor Tuanku Muhriz UKM (HCTM-UKM) framed HPV vaccination, screening, and education as the pillars of prevention in the fight against cervical cancer. The interactive dialogue, “HPV Vaccination: 1 Injection with 1,000 Protections”, featured Professor Dr. Mohamad Nasir Shafiee and Professor Dr. Nirmala Kampan, Consultant Obstetricians and Gynecologists at HCTM-UKM, alongside cervical cancer survivor, Ms. Sharifah Nurul Huda. Together, they highlighted the urgent need to improve vaccine acceptance, expand access, and dispel misconceptions that remain a barrier to protection against HPV-related cancers.

STUDY DESIGN  International guidelines recommend maintaining anticoagulation for cancer-associated thrombosis for the duration of active malignancy or ongoing cancer therapy.1 As the risk of recurrent venous thromboembolism (VTE) decreases over time while bleeding risk remains substantial, reduced-

The Hong Kong College of Obstetricians and  Gynaecologists (HKCOG) has recently updated its guidelines on the prevention and screening of cervical cancer.¹ The latest recommendations incorporated recent evidence on the role of co-testing with human papillomavirus (HPV)-based screening and cytology-based screening.¹ In an interview with Omnihealth Practice, Dr. Wong, Ching-Yin Grace shared the rationale behind co-testing as the preferred testing modality in  The Family Planning Association of Hong Kong as it offers concurrent triaging. The combination of sensitivity with HPV tests and the specificity with cytology tests allows for a more lenient screening schedule for women in Hong Kong without compromising the benefit of cervical cancer detection.

The noninferior immunogenic responses of the 9-valent human papillomavirus (9vHPV) vaccine among adolescents boys compared with adolescent girls observed in Study V503-002 hinted at the vaccine’s potential efficacy in preventing HPV infections and related diseases for young man as well.1 An extensio

Cervical cancer (CC) is the 4th most common female cancer globally, claiming more than 300,000 women’s lives in 2018.¹ In Hong Kong, the incidence of CC remained high at around 7 per 100,000 women in 2019, which was still below the World Health Organization’s (WHO) target of fewer than 4 per 100,000

Human papillomavirus (HPV) is the most common sexually transmitted infection. In total, more than 40 types of HPV can be transmitted through direct sexual contact, including those types classified as high risk for the development of cervical cancer.¹

Venous thromboembolism (VTE), which includes deep-vein thrombosis and pulmonary embolism, is an important cause of morbidity and mortality amongst patients with cancer.¹ The American Society of Clinical Oncology (ASCO) first